Publication

HOME > Publication > Publication 2017
Publication 2017
  1. Takazono T, Sheppard DC: Aspergillus in chronic lung disease: Modeling what goes on in the airways. Med Mycol. 55(1): 39-47, 2017
  2. Tashiro M, Fushimi K, Kawano K, Takazono T, Saijo T, Yamamoto K, Kurihara S, Imamura Y, Miyazaki T, Yanagihara K, Mukae H, Izumikawa K: Comparison of efficacy of antimicrobial agents among hospitalized patients with Mycoplasma pneumoniae pneumonia in Japan during large epidemics of macrolide-resistant M. pneumoniae infections: A nationwide observational study. Clin Infect Dis. 65: 1837-1842, 2017
  3. Tashiro M, Fushimi K, Kawano K, Takazono T, Saijo T, Yamamoto K, Kurihara S, Imamura Y, Miyazaki T, Yanagihara K, Mukae H, Izumikawa K: Adjunctive Corticosteroid Therapy for Inpatients with Mycoplasma pneumoniae Pneumonia. BMC Pulm Med. 17: 219-219, 2017
  4. Nagayoshi Y, Miyazaki T, Shimamura S, Nakayama H, Minematsu A, Yamauchi S, Takazono T, Nakamura S, Yanagihara K, Kohno S, Mukae H, Izumikawa K: Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species. PLoS One. 12(7): e0180990, 2017
  5. Hirayama T, Takazono T, Iwata K, Senju H, Shimazaki T, Tashiro M, Saijo T, Tanaka T, Nakamura S, Imamura Y, Kojiro M, Miyazaki T, Tsukamoto M, Furumoto A, Morimoto K, Muraosa Y, Matsubara Y, Yanagihara K, Mukae H, Kamei K, Kohno S, Izumikawa K: A case series of histoplasmosis patients with elevated serum soluble interleukin-2 receptor levels. J Infect Chemother. 23(9): 642-647, 2017
  6. Oshima K, Takazono T, Saijo T, Tashiro M, Kurihara S, Yamamoto K, Imamura Y, Miyazaki T, Tsukamoto M, Yanagihara K, Mukae H, Kohno S, Izumikawa K: Examination of cryptococcal glucuronoxylomannan antigen in bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients. Med Mycol. 56(1): 88-94, 2017
  7. Nakamura S, Miyazaki T, Izumikawa K, Kakeya H, Saisho Y, Yanagihara K, Miyazaki Y, Mukae H, Kohno S: Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with Influenza A and B viruses: a multicenter, randomized, controlled study. Open Forum Infect Dis. 4(3): ofx129, 2017
  8. Nishikawa H, Fukuda Y, Mitsuyama J, Tashiro M, Tanaka A, Takazono T, Saijo T, Yamamoto K, Nakamura S, Imamura Y, Miyazaki T, Kakeya H, Yamamoto Y, Yanagihara K, Mukae H, Kohno S, Izumikawa K: In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemoth. 72(6): 1709-1713, 2017
  9. Oshima K, Nakamura S, Iwanaga N, Takemoto K, Miyazaki T, Yanagihara K, Miyazaki Y, Mukae H, Kohno S, Izumikawa K: Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 61(1): pii: e02056-16,doi: 10.1128/AAC. 02056-16, 2017
  10. Higashi Y, Nakamura S, Ashizawa N, Oshima K, Tanaka A, Miyazaki T, Izumikawa K, Yanagihara K, Yamamoto Y, Miyazaki Y, Mukae H, Kohno S: Pulmonary Actinomycosis mimicking pulmonary aspergilloma and a brief review of the literature. Intern Med. 56(4): 449-453, 2017
  11. Kaku N, Morinaga Y, Takeda K, Kosai K, Uno N, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K: Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. J Antimicrob Chemother. 72(4): 1123-1128, 2017
  12. Kosai K, Kaku N, Uno N, Saijo T, Morinaga Y, Imamura Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K: Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in Pseudomonas aeruginosa. Open Microbiol J 31(11): 92-97, 2017
  13. Kajihara T, Nakamura S, Iwanaga N, Oshima K, Hirano K, Miyazaki T, Izumikawa K, Yanagihara K, Miyazaki Y, Hattori N, Kohno N, Kohno S, Mukae H: Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis. J Infect Chemoth 23(7): 498-501, 2017
  14. Kaku N, Kosai K, Takeda K, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K: Efficacy and pharmacokinetics of the combination of OP0595 and cefepime in a mouse model of pneumonia caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae. Antimicrob Agent Chemoth 61(7): e00828-17, 2017
  15. Takeda K, Kaku N, Morinaga Y, Kosai K, Uno N, Imamura Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K: Tedizolid inhibits MUC5AC production induced by methicillin-resistant Staphylococcus aureus in human airway epithelial cells. J Infect Chemoth. 23(9): 598-603, 2017
  16. Kosai K, Iwanaga Y, Akamatsu N, Okada Y, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K: Performance evaluation of the Verigene®Clostridium difficile nucleic acid test, an automated multiplex molecular testing system for detection of C. difficile toxin. J Infect Chemoth. 23(10): 674-677, 2017
  17. Ide S, Sakamoto N, Hara S, Hara A, Kakugawa T, Nakamura Y, Futsuki Y, Izumikawa K, Ishimatsu Y, Yanagihara K, Mukae H: Interstitial Lung Disease Induced by Pazopanib Treatment. Intern Med. 56(1): 79-83, 2017
  18. Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, Morinaga Y, Izumikawa K, Kohno S. Quantitative detection of periodontopathic bacteria in lower respiratory tract specimens by real-time PCR. J Infect Chemother. 2017 Feb;23(2):69-73.
  19. Taniguchi D, Yamasaki N, Miyazaki T, Tsuchiya T, Matsumoto K, Hatachi G, Kakugawa T, Sakamoto N, Mukae H, Nagayasu T: The surgical outcomes of lung cancer combined with interstitial pneumonia: a single-institution report. Surg Today. 47(11): 1397-1404, 2017